NAD+ and Longevity: A Review of Current Pre-Clinical Research

Nicotinamide adenine dinucleotide (NAD+) has been one of the most active areas in pre-clinical longevity research over the past fifteen years. As the principal hydride-accepting coenzyme in cellular metabolism and an obligate substrate for the sirtuin family of deacylases, NAD+ sits at the intersection of bioenergetics and metabolic signaling. This article reviews the published research on NAD+ in pre-clinical models of aging, summarizes the sirtuin pathway and mitochondrial findings that have driven the field, and outlines laboratory handling considerations for research-grade NAD+ material.

What is NAD+?

NAD+ is a dinucleotide composed of two nucleotides joined through their phosphate groups, one with an adenine base and the other with a nicotinamide moiety. The reduced form, NADH, carries two electrons and one proton equivalent. The NAD+/NADH ratio is a central determinant of cellular redox state and is sensed by a wide range of enzymes that translate redox status into transcriptional and post-translational responses.

Beyond its role as a hydride carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation, NAD+ is consumed (not merely interconverted) by three classes of NAD+-dependent enzymes: the sirtuins (SIRT1–SIRT7), the PARPs (poly-ADP-ribose polymerases), and the cyclic ADP-ribose synthases (CD38, CD157). This consumption means that cellular NAD+ levels can be depleted by sustained activation of any of these enzymes, with downstream consequences for metabolism and signaling.

The Sirtuin Pathway

The sirtuin family was identified through yeast genetic screens for lifespan-extending mutations and subsequently characterized in mammals. Mammalian SIRT1, SIRT3, and SIRT6 have attracted the most pre-clinical research attention. SIRT1 deacetylates histones and a wide range of transcription factors implicated in metabolism (FOXO, PGC-1α, p53). SIRT3 is mitochondrial and deacetylates substrates in fatty acid oxidation, antioxidant defense, and oxidative phosphorylation. SIRT6 has been linked to telomere maintenance, DNA repair, and inflammatory signaling.

All sirtuins require NAD+ as a cosubstrate, and crucially, their kinetics are sensitive to physiologically relevant changes in NAD+ concentration. This dependency is the molecular basis for the hypothesis that NAD+ availability is a control point for metabolic and longevity signaling.

Pre-Clinical Observation: NAD+ Decline with Age

A consistent finding across pre-clinical models, including rodents, dogs, and non-human primates, is that tissue NAD+ levels decline with age. This decline has been observed across diverse tissues (liver, skeletal muscle, brain, heart) and has been mechanistically linked to increased age-related activation of NAD+-consuming enzymes, particularly CD38, alongside decreased de novo and salvage pathway NAD+ synthesis.

The functional consequence of this decline, as documented in pre-clinical models, includes reduced sirtuin activity, mitochondrial dysfunction as measured by respirometry and mitochondrial DNA copy number, and changes in metabolic flexibility. These observations have motivated a substantial body of research on whether elevating NAD+ availability in aged animals can restore aspects of younger-tissue phenotype.

Pre-Clinical Findings on NAD+ Restoration

Multiple lines of pre-clinical research have examined strategies for elevating tissue NAD+ in aged animals. The most common approaches use NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), but research has also been published on direct NAD+ administration in pre-clinical settings.

Published findings in rodent models have included:

• Restoration of mitochondrial respiratory capacity in aged skeletal muscle and liver
• Improved glucose tolerance and insulin sensitivity in DIO and aged rodent models
• Effects on neurological endpoints including cognitive performance in aged-rodent paradigms and improvements in some neurodegeneration models
• Cardiovascular endpoints including improved endothelial function in aged-vessel preparations
• Effects on body composition with reduced age-related adiposity in some studies

The pre-clinical landscape is broad and not uniformly positive: some studies have failed to reproduce key findings, and the field continues to debate the relative contributions of restored sirtuin activity, restored bioenergetics, and other NAD+-dependent processes.

Mitochondrial Research

A central thread in the pre-clinical NAD+ literature is the relationship between NAD+ availability and mitochondrial function. Mitochondria both consume NAD+ (through oxidative phosphorylation and SIRT3-mediated post-translational modification of mitochondrial enzymes) and are sensitive to NAD+ availability for biogenesis and quality control. Pre-clinical work has reported that NAD+ restoration in aged animals improves mitochondrial respiratory capacity, increases mitochondrial DNA copy number, and modulates expression of nuclear-encoded mitochondrial genes via PGC-1α.

Laboratory Handling and Stability Considerations

Lyophilized Material

NAD+ is supplied as lyophilized white powder. Lyophilized NAD+ stored sealed at 2–8°C, protected from moisture and light, is reported to retain integrity for extended periods; longer-term storage at -20°C is the standard recommendation.

Reconstitution

For research use, reconstitution with bacteriostatic water or sterile water for irrigation is standard. NAD+ in solution at neutral pH is less stable than the lyophilized form, and stability data for the chosen solvent system should be confirmed at the laboratory level. Working solutions are generally stored at 2–8°C and used within a short defined window.

Purity Verification

Research-grade NAD+ should be supplied with a lot-specific Certificate of Analysis demonstrating purity by reversed-phase HPLC, identity confirmation by mass spectrometry, and endotoxin assessment by LAL. Neo Labs publishes the third-party Kovera Labs COA for every NAD+ batch on the NAD+ product page. The current Kovera Labs batch 052026 NAD+ material is reported at >99.2% purity by HPLC.

Research Use Disclaimer

The information above summarizes published pre-clinical research on NAD+ biology and longevity-relevant endpoints. NAD+ as supplied for research is not approved by the U.S. Food and Drug Administration for any therapeutic indication. Materials supplied by Neo Labs are intended exclusively for qualified in vitro and laboratory research. They are not for human consumption, clinical use, or veterinary application. Researchers are responsible for compliance with all applicable institutional and regulatory requirements.

Selected References

• Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol.
• Yoshino J, Baur JA, Imai S. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab.
• Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science.
• Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab.